Understanding Advanced Prostate Cancer Decision Making Utilizing an Interactive Decision Aid.

Cancer Nurs

Author Affiliations: School of Nursing (Drs Jones and Hollen and Ms Sims) and School of Medicine (Dr Weiss), University of Virginia, Charlottesville; School of Nursing (Dr Wenzel) and School of Medicine (Dr Daniel Song), Johns Hopkins University, Baltimore, Maryland; and Public Health Sciences, University of Virginia, Charlottesville (Dr Petroni).

Published: August 2018

AI Article Synopsis

  • * This study explored the experiences of 35 patient-decision partner pairs using a tool called DecisionKEYS to help them make informed and shared treatment choices.
  • * Key findings showed that the decision aid improved understanding of options, prioritized quality of life over quantity, and highlighted the significant impact of healthcare provider interactions on decision-making.

Article Abstract

Background: Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths among men in the United States. Patients with advanced prostate cancer are vulnerable to difficult treatment decisions because of the nature of their disease.

Objective: The aims of this study were to describe and understand the lived experience of patients with advanced prostate cancer and their decision partners who utilized an interactive decision aid, DecisionKEYS, to make informed, shared treatment decisions.

Methods: This qualitative study uses a phenomenological approach that included a sample of 35 pairs of patients and their decision partners (16 pairs reflected patients with <6 months since their diagnosis of metastatic castration-resistant prostate cancer; 19 pairs reflected patients with >6 months since their diagnosis of metastatic castration-resistant prostate cancer). Qualitative analysis of semistructured interviews was conducted describing the lived experience of patients with advanced prostate cancer and their decision partners using an interactive decision aid.

Results: Three major themes emerged: (1) the decision aid facilitated understanding of treatment options; (2) quality of life was more important than quantity of life; and (3) contact with healthcare providers greatly influenced decisions.

Conclusions: Participants believed the decision aid helped them become more aware of their personal values, assisted in their treatment decision making, and facilitated an interactive patient-healthcare provider relationship.

Implications For Practice: Decision aids assist patients, decision partners, and healthcare providers make satisfying treatment decisions that affect quality/quantity of life. These findings are important for understanding the experiences of patients who have to make difficult decisions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411342PMC
http://dx.doi.org/10.1097/NCC.0000000000000442DOI Listing

Publication Analysis

Top Keywords

prostate cancer
24
advanced prostate
16
decision aid
16
decision partners
16
decision
12
cancer decision
12
interactive decision
12
patients advanced
12
cancer
8
decision making
8

Similar Publications

Purpose: A novel theranostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), [Ga]Ga/[Lu]Lu-NYM032, was developed and its diagnostic and therapeutic potential in the treatment of prostate cancer (PCa) was preliminarily evaluated.

Methods: The diagnostic efficacy of the PET tracer [Ga]Ga-NYM032 was first evaluated in PSMA-positive xenograft-bearing models (LNCaP models), followed by evaluation in 10 PCa patients using [Ga]Ga-PSMA617 a comparator. Finally, the therapeutic potential of [Lu]Lu-NYM032 was evaluated in LNCaP models.

View Article and Find Full Text PDF

Background: Prostate cancer therapy with surgical or chemical castration with GnRH agonists has been linked to elevated FSH levels, which may contribute to secondary health disorders, including atherosclerosis and diabetes. Although recent findings suggest a role for FSH beyond the reproductive system, its metabolic impact remains unclear and difficult to disentangle from that of androgens. In this study, we examined the metabolic changes induced by FSH and distinguished them from those caused by testosterone.

View Article and Find Full Text PDF

Purpose: 10-15% of prostate cancers (PCa) harbor recurrent FOXA1 aberrations whereby the alteration type and the effect on the forkhead( FKH) domain impacts protein-function. We developed a FOXA1 classification system to inform clinical management.

Experimental Design: 5,014 PCa were examined using whole exome and transcriptome sequencing from the Caris database.

View Article and Find Full Text PDF

A new effLuc/Kate dual reporter allele for tumour imaging in mice.

Dis Model Mech

January 2025

Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna (MUW), Vienna, Austria.

Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the micro-environment is paramount to achieve a better spatiotemporal understanding of cancer progression and to evaluate therapies in preclinical studies. Bioluminescent and fluorescent reporters marking tumor cells or their microenvironment are valuable for non-invasive cell detection and monitoring in vivo.

View Article and Find Full Text PDF

This study aims to investigate the effect and mechanism of cyclosporine A (CsA) on paclitaxel-resistant prostate cancer cells. Paclitaxel-resistant prostate cancer cell lines were established by gradual increment method. The proliferation of cells was tested using MTT and colony formation assay.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!